LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer
Por:
Avilés-Salas A., Díaz-García D.A., Lara-Mejía L., Cardona A.F., Orozco-Morales M., Catalán R., Hernández-Pedro N.Y., Rios-Garcia E., Ramos-Ramírez M., Arrieta O.
Publicada:
1 ene 2023
Categoría:
Oncology
Resumen:
(1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistry as a potential biomarker. (2) Methods: This bicentric retrospective cohort study analyzed data from patients with advanced NSCLC who initiated platinum-based chemotherapy or epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) between January 2016 and December 2020. Kaplan–Meier and Cox regression models were used for survival curves and multivariate analysis. (3) Results: 110 patients were evaluated, and the clinical stage IV predominated the lung adenocarcinoma histology. LKB1 loss was observed in 66.3% of cases. LKB1 loss was associated with non-smokers, the absence of wood smoke exposure and an EGFR wild-type status. The median progression-free survival (PFS) and overall survival (OS) in the population were 11.1 and 26.8 months, respectively, in the loss group, compared with cases exhibiting a positive expression. After an adjustment by age, smoking status, Eastern Cooperative Oncology Group Performance Score (ECOG-PS), EGFR status and type of administered therapy, LKB1 loss was significantly associated with worse PFS and OS. (4) Conclusion: Patients with an LKB1 loss had worse clinical outcomes. This study warrants prospective assessments to confirm the prognostic role of the LKB1 expression in advanced NSCLC. © 2022 by the authors.
Filiaciones:
Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, 14080, Mexico
Personalized Medicine Laboratory, Instituto Nacional de Cancerología (INCan), Mexico City, 14080, Mexico
Direction of Research and Education, Luis Carlos Sarmeinto Angulo Cancer Treatment and Research Center—CTIC, Bogotá, 110131, Colombia
Neuroimmunology Laboratory, Instituto Nacional de Neurología y Neurocirugía, Mexico City, 14269, Mexico
All Open Access; Gold Open Access; Green Open Access
|